Prime Medicine Inc (PRME)
7.085
+0.04
(+0.64%)
USD |
NASDAQ |
May 17, 16:00
7.085
0.00 (0.00%)
After-Hours: 20:00
Prime Medicine Free Cash Flow (Quarterly): -70.03M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -70.03M |
| December 31, 2023 | -45.70M |
| September 30, 2023 | -42.08M |
| June 30, 2023 | -42.80M |
| March 31, 2023 | -43.56M |
| Date | Value |
|---|---|
| December 31, 2022 | -35.53M |
| September 30, 2022 | -34.89M |
| June 30, 2022 | -25.02M |
| March 31, 2022 | -52.48M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-70.03M
Minimum
Mar 2024
-25.02M
Maximum
Jun 2022
-43.57M
Average
-42.80M
Median
Jun 2023
Free Cash Flow (Quarterly) Benchmarks
| Pacific Biosciences of California Inc | -79.56M |
| 10x Genomics Inc | -18.64M |
| Recursion Pharmaceuticals Inc | -108.95M |
| Verve Therapeutics Inc | -43.52M |
| Ginkgo Bioworks Holdings Inc | -95.97M |